Company news

Adaptive Biotechnologies Corporation news in 2022

Adaptive Biotechnologies Corporation's news releases, calls and decks from 2022, newest first.

View company

Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 26, 2022

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

December 9, 2022

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

December 4, 2022

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

November 30, 2022

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

November 20, 2022

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

November 2, 2022

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

October 10, 2022

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

October 4, 2022

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

September 11, 2022

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

September 1, 2022

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

August 2, 2022

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

July 27, 2022

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

July 7, 2022

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

June 14, 2022

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology

June 1, 2022

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

May 3, 2022

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

May 1, 2022

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

April 4, 2022

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

March 8, 2022

Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference

March 1, 2022

Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

February 17, 2022

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

February 14, 2022

Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 1, 2022

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

January 23, 2022

Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition

January 9, 2022

Calls in 2022

Decks in 2022